BioSyent acquires Oral Science

BioSyent Inc., a publicly traded Canadian specialty healthcare company, has completed the acquisition of Oral Science Inc., a distributor of dental hygiene and oral health products. The acquisition, valued at CAD 25.5 million (approximately USD 26 million), was finalized following a Share Purchase Agreement dated February 8, 2026. The deal positions BioSyent to expand its footprint in the oral health sector through the addition of Oral Science's specialized portfolio.

Under the terms of the transaction, BioSyent executed the acquisition through its wholly-owned subsidiary, paying CAD 22.5 million in cash to Oral Science's shareholders. Part of this cash payment, CAD 0.2 million, will be delivered as Restricted Share Units (RSUs) to certain Oral Science employees, set to vest fully by 2028. Additionally, BioSyent issued 234,192 of its shares, valued at CAD 12.81 each, to complete the transaction. Of these shares, 167,635 are escrow-bound for two years, while another 66,557 are subject to a staggered release over the same period. BioSyent also provided an immediate cash adjustment for excess working capital worth CAD 2 million and has agreed to possible future earn-out and royalty payments, contingent on Oral Science's performance and sales.

BioSyent's acquisition of Oral Science aligns with its strategy to bolster its oral health business unit by integrating partnerships with innovative dental practices. Oral Science's established approach across diagnosis, treatment, home-care solutions, and educational initiatives complements BioSyent's market strategy of enhancing clinical outcomes in oral health. This acquisition represents BioSyent's commitment to strengthening and diversifying its portfolio with evidence-based products.

In a healthcare sector marked by a growing focus on dental health, this acquisition could increase competitive pressures on companies offering similar in-office and at-home dental solutions. By incorporating Oral Science's offerings, BioSyent aims to leverage synergies and potentially drive higher market penetration, especially as demand for advanced oral healthcare solutions continues to grow. The funding structure of the deal, combining liquid reserves and bank financing, demonstrates BioSyent's prudent capital management amidst a competitive landscape.

Final approval of the acquisition is pending from the TSX Venture Exchange under its Expedited Acquisition guidelines. As BioSyent seeks to integrate Oral Science's operations, attention will be on executing strategic alignment while monitoring market reactions to this expansion initiative. Further performance-based contingent payments and their potential impacts on BioSyent's financial results will be examined as Oral Science's business metrics unfold over the coming years.